ThromboGenics Initiates Two Phase II Clinical Trials for SY162 in Two Separate Indications, Catheter Occlusion and Acute Peripheral Arterial Occlusive Disease (PAOD)

Apr 19, 2001, 01:00 ET from ThromboGenics Ltd.

    DUBLIN, Ireland, April 19 /PRNewswire/-- ThromboGenics Ltd. today
 announced the initiation of 2 separate clinical trials for SY162, a novel
 thrombolytic (clot-dissolving) agent.  One of these early Phase II trials will
 evaluate SY162 for the treatment of central venous catheter (CVC) occlusion,
 while the other will evaluate SY162 for the treatment of acute peripheral
 arterial occlusive disease (PAOD).
     "The initiation of these trials marks a significant milestone in the
 history of ThromboGenics," stated Desire Collen, M.D., Ph.D., cofounder and
 CEO of ThromboGenics.  "The company has now advanced 3 programs into Phase II
 clinical development.  This serves as an important validation of the company's
 ability to efficiently move compounds into the clinic."
     The CVC trial will enroll approximately 48 patients, while the PAOD trial
 will enroll approximately 20 patients.  Both trials are being performed in
 Belgium.  Medisearch International has been contracted to monitor both trials.
     "The medical community currently has very limited treatment options for
 either PAOD or CVC occlusion," commented Steve Pakola, M.D., ThromboGenics'
 Vice President of Clinical Development.  "We believe SY162 has the potential
 to fill an unmet need in both of these indications."
     Acute PAOD is associated with significant mortality and morbidity.
 Treatment options include surgical intervention and intra-arterial
 administration of a thrombolytic agent.  Intra-arterial thrombolysis has the
 potential advantage of reducing the need for surgery, or for patients who
 still require surgery after thrombolysis, permitting a less extensive surgical
 procedure.
     CVCs are access devices for chronic administration of medication and for
 withdrawal of blood for laboratory testing.  In excess of 5 million such
 devices are inserted per year in the United States alone.  CVC malfunction
 (primarily due to thrombotic occlusion) is a common complication requiring
 intervention.  Surgical intervention has numerous disadvantages, which make
 salvage of the occluded CVC via thrombolysis the preferred treatment option.
 Because of its unique mechanism of fibrin-specificity, SY162 may prove
 attractive for the treatment of both CVC malfunction and PAOD.
 
     ThromboGenics Ltd., based in Dublin, Ireland, is a privately-held company
 focused on developing drugs for the treatment of cardiovascular diseases.  The
 company's lead program, PEG-Sak (pegylated staphlyokinase variant) for
 treatment of acute myocardial infarction (AMI), is currently being evaluated
 in a large, Phase II trial.  In addition to PEG-Sak and SY162, the company has
 5 additional programs in pre-clinical development for thromboembolic diseases,
 including acute coronary syndromes and stroke.  The company's pipeline
 programs are based on a novel discovery platform that utilizes gene knock-out
 technology to identify new targets for drug development.  The company will
 continue to utilize this platform for the discovery of additional programs to
 add to its pipeline.
     Additional company information is available at
 http://www.thrombogenics.com.
 
 

SOURCE ThromboGenics Ltd.
    DUBLIN, Ireland, April 19 /PRNewswire/-- ThromboGenics Ltd. today
 announced the initiation of 2 separate clinical trials for SY162, a novel
 thrombolytic (clot-dissolving) agent.  One of these early Phase II trials will
 evaluate SY162 for the treatment of central venous catheter (CVC) occlusion,
 while the other will evaluate SY162 for the treatment of acute peripheral
 arterial occlusive disease (PAOD).
     "The initiation of these trials marks a significant milestone in the
 history of ThromboGenics," stated Desire Collen, M.D., Ph.D., cofounder and
 CEO of ThromboGenics.  "The company has now advanced 3 programs into Phase II
 clinical development.  This serves as an important validation of the company's
 ability to efficiently move compounds into the clinic."
     The CVC trial will enroll approximately 48 patients, while the PAOD trial
 will enroll approximately 20 patients.  Both trials are being performed in
 Belgium.  Medisearch International has been contracted to monitor both trials.
     "The medical community currently has very limited treatment options for
 either PAOD or CVC occlusion," commented Steve Pakola, M.D., ThromboGenics'
 Vice President of Clinical Development.  "We believe SY162 has the potential
 to fill an unmet need in both of these indications."
     Acute PAOD is associated with significant mortality and morbidity.
 Treatment options include surgical intervention and intra-arterial
 administration of a thrombolytic agent.  Intra-arterial thrombolysis has the
 potential advantage of reducing the need for surgery, or for patients who
 still require surgery after thrombolysis, permitting a less extensive surgical
 procedure.
     CVCs are access devices for chronic administration of medication and for
 withdrawal of blood for laboratory testing.  In excess of 5 million such
 devices are inserted per year in the United States alone.  CVC malfunction
 (primarily due to thrombotic occlusion) is a common complication requiring
 intervention.  Surgical intervention has numerous disadvantages, which make
 salvage of the occluded CVC via thrombolysis the preferred treatment option.
 Because of its unique mechanism of fibrin-specificity, SY162 may prove
 attractive for the treatment of both CVC malfunction and PAOD.
 
     ThromboGenics Ltd., based in Dublin, Ireland, is a privately-held company
 focused on developing drugs for the treatment of cardiovascular diseases.  The
 company's lead program, PEG-Sak (pegylated staphlyokinase variant) for
 treatment of acute myocardial infarction (AMI), is currently being evaluated
 in a large, Phase II trial.  In addition to PEG-Sak and SY162, the company has
 5 additional programs in pre-clinical development for thromboembolic diseases,
 including acute coronary syndromes and stroke.  The company's pipeline
 programs are based on a novel discovery platform that utilizes gene knock-out
 technology to identify new targets for drug development.  The company will
 continue to utilize this platform for the discovery of additional programs to
 add to its pipeline.
     Additional company information is available at
 http://www.thrombogenics.com.
 
 SOURCE  ThromboGenics Ltd.